Become A Featured Company

Emerald Health Launches New Products in Bid to Become Market Leader

Ryan Allway

May 26th, 2017

News, Top News

Canada’s cannabis industry is expected to exceed C$20 billion over the coming years as the country implements recreational legalization. At the same time, analysts project that there will be a shortfall in supply that could boost the prospects of licensed producers. The best opportunities may be companies that have significant capacity for production, as well as innovative products and technologies that could serve as barriers to entry over time.

In this article, we will take a look at Emerald Health Therapeutics Inc.’s (TSX-V: EMH) newly launched cannabidiol (CBD) products and its long-term plan to become a market leader.

Best-in-Class Products

Emerald Health recently announced the launch of its CBD-25 and CBD-50 medical cannabis oils that contain 25mg and 50mg of CBD per milliliter. Management believes that these oils contain the highest concentration of CBD per ml among approved Canadian products and establish the company as a leader in the CBD segment. The team plans to further refine the products by developing them into capsules that may be more broadly palatable.

“These high CBD oils have minute amounts of THC and thus little to no psychoactive effects,” says Emerald Health President & CEO Dr. Bin Huang. “Emerald is also actively developing capsules that will have the advantage of precise dosing in a format familiar to patients and doctors. We believe that capsules are the ideal form of delivery for patients with little or no experience with cannabis and will become the preferred delivery method.”

The new launch follows the company’s collaboration with the Canadian National Research Council’s Industrial Research Assistance Program. Under the program, the company secured federal funding to support the research and development of cannabinoid product lines with a high level of genetic and product diversity. The hope is to develop both CBD and THC-based products designed to target a wide range of medical conditions.

Ambitious Expansion Plans

Canada’s cannabis industry is expected to achieve significant growth over the coming years, particularly as recreational legalization goes into effect next year. According to Deloitte, the industry could mushroom into a C$22.6 billion per year industry when factoring in growers, retailers, and ancillary product and service providers. At the same time, PI Financial believes that the industry could experience a shortfall in production with just ~40 licensed producers.

“Emerald supports the federal government’s legislative initiative to legalize, regulate, and restrict access to cannabis by the Canadian public,” says Dr. Huang. “Legalization is a considerable undertaking that will touch all aspects of Canadian society and has the potential to be viewed around the world as the leading benchmark for adult-use cannabis regulated at a national level. As one of 44 licensed producers, we are pleased to see the federal government’s recognition of good production practices and desire to establish an efficient cross-country cannabis market.”

Emerald Health plans to address the potential shortfall by rapidly expanding its cultivation space prior to legalized sales under the proposed regulatory framework. Currently, the company is executing on its Phase 1 and Phase 2 plans to add 100,000 sq. ft. of purpose-built hybrid greenhouse space on 32 acres. With nearly C$40 million in the bank, the company plans to accelerate these plans to build 1+ million sq. ft. of production on its sprawling property.

Looking Ahead

Emerald Health Therapeutics Inc. (TSX-V: EMH) aims to become a major player in both the medical and recreational cannabis markets by developing unique products with new delivery technologies and standardized dosing. At the same time, the company plans to advance clinical trials to support its therapeutics and tap into deeper medical markets as cannabis flower becomes commoditized over time.

For more information, visit the company’s website or CannabisFN’s company profile.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading